Companies › Industrial Farmacéutica Cantabria
1 active drug program in 4 registered trials: 1 Phase 3, 1 Phase 4, 1 Phase 2, 1 Phase 1; Immunology, Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Minoxidil Sulfonylurea receptor 2, Kir6.2 opener | Ion channels, ABCC9 | Phase 3 | Androgenetic Alopecia; Central Centrifugal Cicatricial Alopecia (CCCA); Survivors of Childhood Cancer; Breast Reconstruction | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04207931 | Minoxidil | Phase 4 | Central Centrifugal Cicatricial Alopecia (CCCA) | Immunology | Nov 2026 |
| NCT05888922 | Minoxidil | Phase 3 | Androgenetic Alopecia | Immunology | Nov 2026 |
| NCT05778825 | Minoxidil | Phase 2 | Survivors of Childhood Cancer | Oncology | Mar 2027 |
| NCT07264790 | Minoxidil | Phase 1 | Breast Reconstruction | Oncology | Sep 2027 |
Zhejiang Sunshine Mandi Pharmaceutical VM Therapeutics Antengene Biologics Ganzhou Hemay Pharmaceutical Jiangsu vcare pharmaceutical technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.